Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer

Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab

(2011) J. Pander et al.   CLINICAL CANCER RESEARCH

The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time

(2010) Junliang Ma et al.   BMC CANCER

Hyaluronan Deficiency in Tumor Stroma Impairs Macrophage Trafficking and Tumor Neovascularization

(2010) N. Kobayashi et al.   CANCER RESEARCH

Macrophage Diversity Enhances Tumor Progression and Metastasis

(2010) Bin-Zhi Qian et al.   CELL

Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Adenocarcinoma

(2010) K. Kasahara et al.   CLINICAL CANCER RESEARCH

Macrophages, innate immunity and cancer: balance, tolerance, and diversity

(2010) Alberto Mantovani et al.   CURRENT OPINION IN IMMUNOLOGY

NF-κB as a central regulator of macrophage function in tumors

(2010) Subhra K. Biswas et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Stromal Macrophage Expressing CD204 is Associated with Tumor Aggressiveness in Lung Adenocarcinoma

(2010) Yoichi Ohtaki et al.   Journal of Thoracic Oncology

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-Density Gene Expression Analysis of Tumor-Associated Macrophages from Mouse Mammary Tumors

(2009) Laureen S. Ojalvo et al.   AMERICAN JOURNAL OF PATHOLOGY

Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

(2009) W. Wang et al.   CLINICAL CANCER RESEARCH

Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival

(2009) C. M. Ohri et al.   EUROPEAN RESPIRATORY JOURNAL

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

(2009) Rafael Rosell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predominant infiltration of macrophages and CD8+T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer

(2008) Osamu Kawai et al.   CANCER

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

(2008) Edward S Kim et al.   LANCET

Expression of CD68 in Non-Myeloid Cell Types

(2008) E. Gottfried et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY